



Substitute for form 1470 PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
Sheet	1	of	3	Application Number	10/719,692
				Filing Date	November 21, 2003
				First Named Inventor	An, Songzhu
				Art Unit	1645
				Examiner Name	Not yet assigned
				Attorney Docket Number	018781-009530US

U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	US-6,500,938	B1	12-31-2002	Au-Young, et al.	
	A2	US-6,555,339	B1	04-29-2003	Liaw, et al.	
	A3	US-2002-0052022	A1	05-02-2002	Elshourbagy, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup>			
	A4	EP	1270724	A2	01-02-2003	1) National Institute of Advanced Industrial Science and Technology; and 2) Center for Advanced Science and Technology Incubation, Ltd.
	A5	WO	98/56820	A1	12-17-1998	Smithkline Beecham Corporation
	A6	WO	00/22129	A1	04-20-2000	Arena Pharmaceuticals, Inc.
	A7	WO	01/36471	A2	05-25-2001	Arena Pharmaceuticals, Inc.
	A8	WO	01/36473	A2	05-25-2001	Pharmacia & Upjohn Company
	A9	WO	01/73029	A2	10-04-2001	PE Corporation
	A10	WO	01/74904	A2	10-11-2001	Curagen Corporation
	A11	WO	01/77320	A2	10-18-2001	Bayer AG
	A12	WO	01/77326	A1	10-18-2001	Takeda Chemical Industries, Ltd.
	A13	WO	01/87937	A2	11-22-2001	Incyte Genomics, Inc.
	A14	WO	01/94385	A2	12-13-2001	Bayer AG
	A15	WO	01/94629	A2	12-13-2001	Avalon Pharmaceuticals
	A16	WO	01/98330	A2	12-27-2001	Euroscreen S.A.
	A17	WO	02/02767	A1	01-10-2002	Takeda Chemical Industries, Ltd.
	A18	WO	02/08486	A1	01-24-2002	Takeda Chemical Industries, Ltd.
	A19	WO	02/13845	A2	02-21-2002	Novartis AG
	A20	WO	02/18579	A2	03-07-2002	Millennium Pharmaceuticals, Inc.
	A21	WO	02/18938	A1	03-07-2002	Boehringer Ingelheim Pharma KG
	A22	WO	02/28999	A2	04-11-2002	Gene Logic, Inc.
	A23	WO	02/081087	A2	08-08-2002	Lifespan Biosciences, Inc.
	A24	WO	02/072755	A2	09-19-2002	Bristol-Myers Squibb Company
	A25	WO	02/084298	A2	10-24-2002	Glaxo Group Limited
	A26	WO	03/021262	A1	03-13-2003	Takeda Chemical Industries, Ltd.

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>10/6/08</i>
--------------------	--------------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

JUN 28 2004

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

**Complete If Known**

Application Number	10/719,692
Filing Date	November 21, 2003
First Named Inventor	An, Songzhu
Art Unit	1645
Examiner Name	Not yet assigned
Attorney Docket Number	018781-009530US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
✓	A27	AKTORIES, K., et al., "Nicotinic Acid Inhibits Adipocyte Adenylate Cyclase in a Hormone-Like Manner", Elsevier/North-Holland Biomedical Press (June 1980), Vol. 115, No. 1, pp. 11-14.	
✓	A28	BALDWIN, G., et al., "Gut Hormones, Growth and Malignancy", Baillière's Clinical Endocrinology and Metabolism (January 1994), Vol. 8, No. 1, pp. 185-214	
✓	A29	BERRIDGE, M., et al., "Inositol Trisphosphate, a Novel Second Messenger in Cellular Signal Transduction", Nature (November 22, 1984), Vol. 312, pp. 315-321.	
✓	A30	BROWN, M., et al., Drugs Used in the Treatment of Hyperlipoproteinemias, Goodman and Gilman (1990) 8 <sup>th</sup> Ed., Ch. 36, pp. 889-891.	
✓	A31	BROWN, W., et al., "Nicotinic Acid and its Derivatives", Medical Research Foundation, Washington, D.C., pp. 189-213.	
✓	A32	BUCK, L., et al., "A Novel Multigene Family May Encode Odorant Receptors: A Molecular Basis for Odor Recognition", Cell, (April 5, 1991), Vol. 65, pp. 175-187.	
✓	A33	DIPALMA, J., et al., "Use of Niacin as a Drug", Annual Review of Nutrition (1991), Vol. 11, pp. 169-187.	
✓	A34	FELLEY-BOSCO, E., et al., "Constitutive Expression of Inducible Nitric Oxide Synthase in Human Bronchial Epithelial Cells Induces c-fos and Stimulates the cGMP Pathway", American Journal of Respiratory Cell and Molecular Biology (1994), Vol. 11, pp. 159-164.	
✓	A35	FONG, T., "Mechanistic Hypotheses for the Activation of G-Protein-Coupled Receptors", Cell Signal (1996), Vol. 8, No. 3, pp. 217-224.	
✓	A36	GEY, K., et al., eds., Metabolic Effects of Nicotinic Acid and its Derivatives. Proceedings from Workshop on the Metabolic Effects of Nicotinic Acid and its Derivatives, Films, Switzerland, March 23-25, 1970, (Publisher, Hans Huber, Bern, Switzerland, 1971).	
✓	A37	KAUZER, L., et al., "Dissociation of the Effects of Nicotinic Acid on Vasodilatation and Lipolysis by a Prostaglandin Synthesis Inhibitor, Indomethacin, in Man", Medical Biology (1978), Vo. 57, pp. 114-117.	
✓	A38	LANES, R., et al., "Acipimox, a Nicotinic Acid Analog, Stimulates Growth Hormone Secretion in Short Healthy Prepubertal Children", Journal of Pediatric Endocrinology & Metabolism (2000), Vol. 13, pp. 1115-1120.	
✓	A39	LEE, D., et al., "Discovery and Mapping of Ten Novel G Protein-Coupled Receptor Genes", Gene (2001), Vol. 275, pp. 83-91.	
✓	A40	LORENZEN, A., et al., "Characterization of a G Protein-Coupled Receptor for Nicotinic Acid", Molecular Pharmacology (2001), Vol. 59, pp. 349-357.	
✓	A41	LORENZEN, A., et al., "G Protein-Coupled Receptor for Nicotinic Acid in Mouse Macrophages", Biochemical Pharmacology (2002), Vol. 64, pp. 645-648.	
✓	A42	MCINTOSH, C., et al., "Glucose-Dependent Insulinotropic Polypeptide Stimulation of Lipolysis in Differentiated 3T3-L1 Cells: Wortmannin-Sensitive Inhibition by Insulin", Endocrinology (1999), Vol. 140, No. 1, pp. 398-404.	

Examiner Signature		Date Considered	10/6/05
--------------------	--	-----------------	---------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<i>Application Number</i>	10/719,692
				<i>Filing Date</i>	November 21, 2003
				<i>First Named Inventor</i>	An, Songzhu
				<i>Art Unit</i>	1645
				<i>Examiner Name</i>	Not yet assigned
Sheet	3	of	3	<i>Attorney Docket Number</i>	018781-009530US

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
2	A43	MIYAI, K., et al., "Synthesis and Antiinflammatory Activity of 6-Oxo-1-(8-D-ribofuranosyl)nicotinic Acid and Related Derivatives", <i>Journal of Medicinal Chemistry</i> (1978), Vol. 21, No. 5, pp. 427-430.		
2	A44	MONZON, J., "Lipolysis in Adipocytes Isolated from Deep and Superficial Subcutaneous Adipose Tissue", <i>Obesity Research</i> (April 2002), Vol. 10, No. 4, pp. 268-289.		
2	A45	MORRIS, A., et al., "Physiological Regulation of G Protein-Linked Signaling", <i>Physiological Reviews</i> (October 1999), Vol. 79, No. 4, pp. 1373-1430.		
2	A48	NOMURA, H., et al., "Molecular Cloning of cDNAs Encoding a LD78 Receptor and Putative Leukocyte Chemotactic Peptide Receptors", <i>International Immunology</i> (1993), Vo. 5, No. 10, pp. 1239-1249.		
2	A47	OFFERMANNS, S., et al., "G $\alpha_{15}$ and G $\alpha_{16}$ Couple a Wide Variety of Receptors to Phospholipase C", <i>The Journal of Biological Chemistry</i> (June 23, 1995), Vol. 270, No. 25, pp. 15175-15180.		
2	A48	SCHAUB, A., et al., "PUMA-G, and IFN- $\gamma$ -inducible Gene in Macrophages is a Novel Member of the Seven Transmembrane Spanning Receptor Superfamily", <i>European Journal of Immunology</i> (2001), Vol. 31, pp. 3714-3725.		
2	A49	STABLES, J., et al., "A Bioluminescent Assay for Agonist Activity at Potentially Any G-Protein-Coupled Receptor", <i>Analytical Biochemistry</i> (1997), Vol. 252, pp. 115-128.		
2	A50	WILKIE, T., et al., "Characterization of G-protein $\alpha$ subunits in the G $\alpha$ Class: Expression in Murine Tissues and in Stromal and Hematopoietic Cell Lines", <i>Proceedings of the National Academy of Sciences of the United States of America</i> (November 1991), Vol. 88, pp. 10049-10053.		

Examiner Signature		Date Considered	10/6/08
--------------------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.